SII to start Covovax trials on 920 children in July

The recombinant nanoparticle protein-based vaccine —NVX-CoV2373 — developed by American biotechnology firm Novavax has been branded as Covovax in India. It will be the fourth Covid-19 vaccine to undergo clinical trials for children in India.

Original source: https://health.economictimes.indiatimes.com/news/pharma/83862321?utm_source=RSS&utm_medium=ETRSS

Related Posts